Search results for "Mucositis"

showing 10 items of 103 documents

Clinical effect of diode laser on peri-implant tissues during non-surgical peri-implant mucositis therapy: Randomized controlled clinical study

2019

Background: The aim of this study is to evaluate the response to the non-surgical treatment of peri-implant mucositis using the diode laser as an adjuvant therapy in patients with implant-supported restorations, in terms of clinical variables, with respect to those patients in whom conventional non-surgical therapy is used. Material and Methods: Randomized controlled clinical trial with simple blind 3 months follow-up. Two groups of patients were established, the non-surgical mechanical debridement of the affected implants was performed in the control group (n = 34) and the diode laser therapy was also performed in the test group (n = 34). The implant was considered the study subject; the v…

0301 basic medicine030103 biophysicsPeri-implant mucositisBleeding on probingDentistryOdontología03 medical and health sciences0302 clinical medicineLáseresStatistical significanceAdjuvant therapymedicineMucositisTecnología médicaGeneral DentistryImplantes dentalesbusiness.industryResearch030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Clinical trialUNESCO::CIENCIAS MÉDICASAnalysis of varianceImplantmedicine.symptomOral SurgerybusinessJournal of Clinical and Experimental Dentistry
researchProduct

Expression of salivary biomarkers in patients with oral mucositis: evaluation by SELDI-TOF/MS.

2016

Objective: This study aims to evaluate changes in proteomic salivary profile of patients with oral mucositis after adjuvant cancer treatments. Materials and Methods: Samples were collected from patients after adjuvant cancer therapies, and were analyzed by means of SELDI/TOF. Patients were separated in two groups: patients affected by mucositis (MUCOSITIS) and patient without mucositis (NO MUCOSITIS). All patients were divided in function of the anticancer treatment: patients who had radiotherapy (MUCOSITIS RADIO), had not radiotherapy (MUCOSITIS NO RADIO), had chemotherapy (MUCOSITIS CHEMO), and those who had not chemotherapy (MUCOSITIS NO CHEMO). Statistical evaluation PCA (Principal Comp…

0301 basic medicineAdultMalemedicine.medical_specialtySalivaPathologymedicine.medical_treatmentGastroenterologySELDI-TOF/MS; biomarker discovery; oral mucositis; saliva; Adult; Aged; Aged 80 and over; Biomarkers; Chemotherapy Adjuvant; Female; Humans; Male; Middle Aged; Neoplasms; Radiation Injuries; Radiotherapy Adjuvant; Saliva; Stomatitis; Spectrometry Mass Matrix-Assisted Laser Desorption-Ionization03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsbiomarker discoverymedicineMucositisHumansRadiation InjurieRadiation InjuriesSalivaGeneral DentistryStomatitisAgedAged 80 and overChemotherapyStomatitisbusiness.industryCancerSELDI-TOF/MSBiomarkerMiddle Agedmedicine.diseaseStomatitiRadiation therapy030104 developmental biologyOtorhinolaryngologyChemotherapy Adjuvant030220 oncology & carcinogenesisSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationBiomarker (medicine)NeoplasmFemaleRadiotherapy AdjuvantbusinessAdjuvantoral mucositiBiomarkersHumanOral diseases
researchProduct

Differential Superiority of Heavy Charged-Particle Irradiation to X-Rays: Studies on Biological Effectiveness and Side Effect Mechanisms in Multicell…

2016

This review is focused on the radiobiology of carbon ions compared to X-rays using multicellular models of tumors and normal mucosa. The first part summarizes basic radiobiological effects, as observed in cancer cells. The second, more clinically oriented part of the review, deals with radiation-induced cell migration and mucositis. Multicellular spheroids from V79 hamster cells were irradiated with X-rays or carbon ions under ambient or restricted oxygen supply conditions. Reliable oxygen enhancement ratios could be derived to be 2.9, 2.8, and 1.4 for irradiation with photons, (12)C(+6) in the plateau region, and (12)C(+6) in the Bragg peak, respectively. Similarly, a relative biological e…

0301 basic medicinePathologymedicine.medical_specialtyCancer Researchcell migrationMotilityReviewBiologylcsh:RC254-28203 medical and health sciences0302 clinical medicinerelative biological effectivenessRadioresistancemedicineRelative biological effectivenessorganotypic tumor and mucosa culturesparticle irradiationCell migrationOxygen enhancement ratio (OER)lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensrelative biological effectiveness (RBE)030104 developmental biologymucositisOncologyradiobiologyCell cultureApoptosis030220 oncology & carcinogenesisCancer cellOxygen enhancement ratioBiophysicsoxygen enhancement ratioFrontiers in Oncology
researchProduct

Bioactive Polyphenols from Pomegranate Juice Reduce 5-Fluorouracil-Induced Intestinal Mucositis in Intestinal Epithelial Cells

2020

Intestinal epithelial cells (IECs) play a pivotal role in maintaining intestinal homeostasis. Different noxious agents, among them also anticancer therapies, can impair intestinal epithelial integrity triggering inflammation and oxidative stress. A frequent complication of chemotherapy is gastrointestinal mucositis, strongly influencing the effectiveness of therapy, increasing healthcare costs, and impairing patients&rsquo

0301 basic medicinegastrointestinal mucositionconutraceuticalPhysiologyClinical BiochemistryInflammationPharmacologymedicine.disease_causeBiochemistryArticleProinflammatory cytokine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMucositisMedicineoxidative stress5-fluorouracilMolecular BiologyPunica granatum L.polyphenolsoxidative strebiologybusiness.industryNitrotyrosinegastrointestinal mucositislcsh:RM1-950intestinal epithelial cellCell BiologyPunica granatum Lmedicine.diseasebiology.organism_classification5‐fluorouracil; Gastrointestinal mucositis; Inflammation; Intestinal epithelial cells; Onconutraceutical; Oxidative stress; Polyphenols; Punica granatum L5‐fluorouracilpolyphenollcsh:Therapeutics. Pharmacology030104 developmental biologychemistryApoptosisPolyphenolinflammation030220 oncology & carcinogenesisPunicaintestinal epithelial cellsmedicine.symptombusinessOxidative stressAntioxidants
researchProduct

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity…

2018

// Gemma Bruera 1, 2 , Silvia Massacese 3 , Stefania Candria 1 , Antonio Galvano 4 , Rosa Manetta 5 , Aldo Victor Giordano 5 , Sergio Carducci 5 , Alessandra Di Sibio 5 , Eugenio Ciacco 3 , Antonio Russo 4 , Enrico Ricevuto 1, 2 and on behalf of Oncology Network ASL1 Abruzzo, Italy 1 Oncology Territorial Care Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy 4 Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, Univers…

0301 basic medicinemedicine.medical_specialtyFOLFIRINOXPhase II studyPhases of clinical research03 medical and health sciences0302 clinical medicineFIr/FOxFIr/FOx; First-line; Metastatic pancreatic ductal adenocarcinoma; Phase II study; Triplet chemotherapyInternal medicinemedicineMucositisPerformance statusbusiness.industryFirst-linemedicine.diseaseGemcitabineOxaliplatinIrinotecan030104 developmental biologyMetastatic pancreatic ductal adenocarcinomaOncology030220 oncology & carcinogenesisLiver functionTriplet chemotherapybusinessResearch Papermedicine.drug
researchProduct

Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric canc…

2018

// Gemma Bruera 1, 2 , Silvia Massacese 3 , Antonio Galvano 4 , Antonella Dal Mas 5 , Stefano Guadagni 6, 2 , Giuseppe Calvisi 5 , Eugenio Ciacco 3 , Antonio Russo 4 , Enrico Ricevuto 1, 2 , on behalf of Oncology Network ASL1 Abruzzo, Italy 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L'Aquila, L'Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy 4 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy 5 Pathology, S. Salva…

0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaDocetaxelNeutropeniametastatic gastric cancerAnd oxaliplatin03 medical and health sciences0302 clinical medicinedocetaxel 5-fluorouracil and oxaliplatinInternal medicinemedicineMucositisdose-finding study5-fluorouracil5-fluorouracil; And oxaliplatin; Docetaxel; Dose-finding study; FD/FOx intensive regimen; First-line triplet chemotherapy; Metastatic gastric cancer; OncologyHypoalbuminemiabusiness.industrymedicine.diseaseOxaliplatinRegimen030104 developmental biologyOncologyDocetaxelFluorouracil030220 oncology & carcinogenesisfirst-line triplet chemotherapyCohortFD/FOx intensive regimenbusinessmedicine.drugResearch PaperOncotarget
researchProduct

Buccal drug delivery: what's new and what does the future hold?

2014

The buccal mucosa is the stratified squamous epithelial tissue inside lining of the cheeks. It is a favorable site of drug absorption since the tissue is non-keratinized, relatively immobile and strongly supplied with blood by a dense capillary-vessel network; moreover, it is highly tolerant to allergens, resistant to potentially harmful agents and has a relatively low enzymatic activity. The tissue consents quick onset of effect, offers an easily accessible and generally well-accepted site for drug delivery, is a useful route of administration in patients in an unconscious state (e.g., when swallowing is impaired), and is suitable for retentive dosage forms of administration. Buccal mucosa…

3003Drugmedia_common.quotation_subjectChemistry PharmaceuticalPharmaceutical ScienceDentistryPharmacologyDosage formRoute of administrationDrug Delivery SystemsPharmacokineticsMucositisMedicineAnimalsHumansBuccal dosage formmedia_commonDosage FormsDrug Carriersbusiness.industryLocoregional/systemic treatmentMedicine (all)Mouth MucosaAdministration BuccalTransmucosal deliveryBuccal administrationmedicine.diseaseBioavailabilityPharmaceutical PreparationsSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryBuccal mucosaDiffusion of InnovationbusinessForecastingTherapeutic delivery
researchProduct

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia

2021

Objectives Genetic variability in anthracycline metabolism could modify the response and safety of acute myeloid leukemia (AML) induction. Methods Polymorphisms in genes that encodes enzymes of anthracyclines metabolic pathway (CBR3: rs1056892, rs8133052, NQO1: rs1800566, NQO2: rs1143684, NOS3: rs1799983, rs2070744) were evaluated in 225 adult de novo AML patients. Results The variant CBR3 rs8133052 was associated with lower hepatotoxicity (P = 0.028). Wild-type genotype of NQO2 rs1143684 was related to higher complete remission (P = 0.014), and the variant allele with greater gastrointestinal toxicity (P = 0.024). However, the variant genotype of NQO1 rs1800566 was associated with mucositi…

Adult0301 basic medicineAnthracycline030226 pharmacology & pharmacyNephrotoxicity03 medical and health sciences0302 clinical medicineGenotypeGeneticsmedicineMucositisHumansIdarubicinAnthracyclinesGenetic variabilityGeneral Pharmacology Toxicology and PharmaceuticsMolecular BiologyAllelesGenetics (clinical)Polymorphism Geneticbusiness.industryInduction chemotherapyMyeloid leukemiaInduction Chemotherapymedicine.diseaseLeukemia Myeloid Acute030104 developmental biologyCancer researchMolecular Medicinebusinessmedicine.drugPharmacogenetics and Genomics
researchProduct

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy…

2020

Anthracycline uptake could be affected by influx and efflux transporters in acute myeloid leukemia (AML). Combinations of single-nucleotide polymorphisms (SNPs) of wild-type genotype of influx transporters (SLC22A16, SLCO1B1) and homozygous variant genotypes of ABC polymorphisms (ABCB1, ABCC1, ABCC2, ABCG2) were evaluated in 225 adult de novo AML patients. No differences in complete remission were reported, but higher induction death was observed with combinations of SLCO1B1 rs4149056 and ABCB1 (triple variant haplotype, rs1128503), previously associated with ABCB1 and SLCO1B1 SNPs. Several combinations of SLCO1B1 and SLC22A16 with ABCB1 SNPs were associated with higher toxicities, includin…

AdultCancer ResearchGenotypeAnthracyclineSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineMucositisHumansMedicineIdarubicinAnthracyclinesProspective StudiesbiologyLiver-Specific Organic Anion Transporter 1business.industryHaplotypeInduction chemotherapyMyeloid leukemiaInduction ChemotherapyHematologymedicine.diseaseMultidrug Resistance-Associated Protein 2Leukemia Myeloid AcuteOncology030220 oncology & carcinogenesisbiology.proteinCancer researchATP-Binding Cassette TransportersbusinessSLCO1B1030215 immunologymedicine.drugLeukemia & Lymphoma
researchProduct

Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II …

2019

Abstract Background Hepatic arterial embolisation therapy (HAET) is a treatment of liver metastases of gastrointestinal neuroendocrine tumours (GI-NETs). HAET increases circulating vascular endothelial growth factor levels. Everolimus is a treatment in NETs that may have antiangiogenic activity. Methods This phase II study was conducted in patients with predominant and progressive liver metastases from GI-NETs. Everolimus was initiated 7–30 days after HAET. The hypothesis was that everolimus after HAET would increase hepatic progression-free survival (hPFS) rate at 24 months from 35% to 50%. Results Among the 74 patients included, 88% had small-bowel primary tumour, 43% had grade I and 57% …

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyLung NeoplasmsPhases of clinical researchAntineoplastic AgentsBone NeoplasmsGastroenterologyStreptozocin03 medical and health scienceschemistry.chemical_compoundHepatic Artery0302 clinical medicineInternal medicineMucositisHumansMedicineIn patientEverolimusChemoembolization TherapeuticTrial registrationPeritoneal NeoplasmsAgedGastrointestinal NeoplasmsAged 80 and overGastrointestinal tractAntibiotics AntineoplasticEverolimusbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseEmbolization TherapeuticProgression-Free SurvivalConfidence intervalVascular endothelial growth factorNeuroendocrine Tumors030104 developmental biologyOncologychemistryDoxorubicin030220 oncology & carcinogenesisFemaleLymph Nodesbusinessmedicine.drugEuropean Journal of Cancer
researchProduct